Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

@article{Chakravarthy2012RanibizumabVB,
  title={Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.},
  author={Usha Chakravarthy and Simon Peter Harding and Chris A. Rogers and Susan M. Downes and Andrew J. Lotery and Sarah Wordsworth and Barnaby C Reeves},
  journal={Ophthalmology},
  year={2012},
  volume={119 7},
  pages={
          1399-411
        }
}
PURPOSE To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). DESIGN Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). PARTICIPANTS People >50 years of age with untreated nAMD in the study eye who read ≥ 25 letters on the Early Treatment Diabetic Retinopathy Study chart. METHODS We… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 290 CITATIONS

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 19 Highly Influenced Citations

  • Averaged 28 Citations per year over the last 3 years

Similar Papers

Loading similar papers…